311 related articles for article (PubMed ID: 24396142)
1. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
[TBL] [Abstract][Full Text] [Related]
2. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
3. The potential of Sutherlandia frutescens for herb-drug interaction.
Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
5. [The drug-drug interaction mediated by efflux transporters and CYP450 enzymes].
Wang C; Liu KX
Yao Xue Xue Bao; 2014 May; 49(5):590-5. PubMed ID: 25151726
[TBL] [Abstract][Full Text] [Related]
6. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Weiss J; Haefeli WE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
[TBL] [Abstract][Full Text] [Related]
7. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
8. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B; Xu JJ; Bi YA; Mireles R; Davidson R; Duignan DB; Campbell S; Kostrubsky VE; Dunn MC; Smith AR; Wang HF
Toxicol Sci; 2009 Apr; 108(2):492-500. PubMed ID: 19223659
[TBL] [Abstract][Full Text] [Related]
9. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Pedersen JM; Matsson P; Bergström CA; Norinder U; Hoogstraate J; Artursson P
J Med Chem; 2008 Jun; 51(11):3275-87. PubMed ID: 18457386
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.
Rendic SP
Arch Toxicol; 2021 May; 95(5):1535-1546. PubMed ID: 33719007
[TBL] [Abstract][Full Text] [Related]
11. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
13. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
[TBL] [Abstract][Full Text] [Related]
14. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
15. Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.
Gupta A; Harris JJ; Lin J; Bulgarelli JP; Birmingham BK; Grimm SW
Antimicrob Agents Chemother; 2016 Oct; 60(10):5986-94. PubMed ID: 27458210
[TBL] [Abstract][Full Text] [Related]
16. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
17. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
[TBL] [Abstract][Full Text] [Related]
18. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
19. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
20. Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition.
Lundquist P; Englund G; Skogastierna C; Lööf J; Johansson J; Hoogstraate J; Afzelius L; Andersson TB
Drug Metab Dispos; 2014 Mar; 42(3):448-58. PubMed ID: 24396144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
